"" The Pimp Is Out For The Summer.....""Peace~ ""
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
""ROFLMFAO""....>>>>ADMD Is Just Flexing<<<<Watch The Real SHOW!!
MM VFIN Shaking Shares Loose For The Bid Here On ADMD!!!!!<<<<<< Don't Be Bamboozled Out Of Your Shares Players!!!!
""Cmoney......Thanks Bro""...<<<<Watch The Whales For Hour #2 Here On ADMD.....The Bid Is Holding Up^ Because The Shares To Be Had On The Bid Is Beginning To Taper Off, Now Its Time For The Assk To Get a Healthy Dose Of Slappage Here On ADMD!!!!!
Funny Thing Is That When Some Body Puts Up a Big Block On The Ask It Gets Taken Down By Guess Who????.....That's Right Bid Sitters,That's Because They Can't Get Filled On The Bid Like They Could a Week Or Two Weeks Ago Anymore....
Enjoy The Ride Up^!
What's More Impressive Is The Volume In The First Hour Of The Session Over 36M Served!!!!!....WOW.., ADMD Screaming ""BUY""
Heck Yea It's Possible Bro!!!!..,Hell ADMD May Test Some .005's Today!!!Any Wave Of Assk Slapping Will Drive This Beast INSANE!!!!
I Agree 100% BH!!!....,Also The Bid Is Really Thickening Now Here On ADMD Which Again Means There Are Little Shares To Be Had On The Bid....,Now The Ask Will Start To Thin Which Is Indicative Of The ""Float Being Locked Down"" Tell..,Tell Sign Of This Is Happening Right Before Our Eyes Bro!
NP Bro......Looks Like The Bid Is Fortifying & It Also Looks Like Shares Are Starting To Dry Up^ On The BID"", Just Like I Said It Would....... Once This Happens The Ask Will Start To Get POUNDED""..,Hard!!!
ADMD Would Then Be On The Fast Track To Pennyland~
It Was Pr'd On 12/23/14,But It Was Probably Submitted Earlier That Month!!!.....FDA ADMD= ""APPROVAL""
""Monster Mega DD ADMD""
Today We Witnessed Another Whale On Bid 26Milly @ .0018 Over 47K This With Other Bids In The Past Getting Filled Over 20Milly a Pop We Can Safely Assume That There's Some Entities Out There That Are Loading Up^ Big Time Behind The Scenes Right Underneath Our Noses Players!...I Can Only Imagine What Will Happen If FDA Approval Hits & These Whales Are Still Out There Lurking Trying To Get In..
It's Going To Be Pandemonium Here On ADMD... I Can See It Know Ask Gapping Up Peeps Chasing ADMD To No End!!...Don't Let This Be YOU""
So With This In Mind Take Your Time & Decipher This Monster DD That's Laid Out In Front Of You & Maybe Then You Willl Come To Your Senses!!!!...>>LMFAO!
""Pimping Hard & Keeping The Game Real""
Corporate Overview:
Advanced Medical Isotope Corporation (AMIC) (ADMD: OTCQB) is a Kennewick, Washington-based late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications. AMIC's focus is on transitioning to full operations upon receipt of FDA clearance for its patented brachytherapy cancer products.
Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. Annual sales of brachytherapy products exceed $1 billion, about half of which are in the United States. AMIC intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though AMIC will evaluate its alternatives before finalizing its plans.
Since 2006, AMIC has been focused on the commercialization of medical isotope technologies. AMIC has explored technologies for the production of medical isotopes and medical applications of isotope technologies including a line of brachytherapy products
incorporating patented technology licensed exclusively to AMIC by Battelle Memorial Institute, developed at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers.
AMIC’s robust intellectual property position includes exclusive rights under 15 patents
that cover manufacturing, processing and applications for medical isotopes.
A prominent team of radiochemists, scientists and engineers, collaborating worldwide
with strategic partners, including national laboratories, universities and private corporations,
lead AMIC’s development efforts. AMIC is proud to have been recognized as a leader in the
development of new isotope technologies by local, state and federal agencies.
Management:
Mr.Katzoroff Is a Financial Guru Players Having This Guy @ The Helm Is Huge PLUS!...& Mr.Jolliff Is The Numbers Guy, He's The One Behind The Scenes Getting The Money We Need To Get The Product To The Market!
Mr.Stevensen The Madd Scientist...This Guy Is a GENIUS"" He'll Be The One Behind The Scenes Bringing New Products To Fruition..He's a Nuclear Pysics Expert!....& Mr.Ludwig, now This Gentlemen Has International Ties Over Seas, So It's Easy To Imagine Who He Can Bring To The Table!!!!!
""Heavy Weight Mr.Su, Now This Guy Here Is The Mastermind Behind The Scenes Of The Isotope R&D Manufacturing...He Works For Pharma GIANTS"" Like Bristol-Myers Squibb..Also Working
As a Senior Scientist For Several Bio-Technology Firms, Including NeoRx, Nycomed-Amersham,And Cellectar, He Developed Various Radiopharmaceuticals, Very Impressive Savvy Scientist Players!!..,& Last But Not Lease,
Mr. Korenko.,Very..,Very Astute Intelligent Man Who Was Educated At One Of The Most Prestigious Colleges In The World ""OXFORD"" He Was Selected As a White House Fellow For The Department Of Defense Reporting To Secretary Cap Weinberger...,So Yes This Guy Has Inside Connection o The Dept Of Health And Human Services Players!!!!!
Board Of Director's:
"" Mr.Spivak What Can I Say Other Than They Call Him The Billion Dollar Man""...,Billions In Acquisitions..,Mergers..,Financing's This Guy Has Worked With Bigg Oil Mobil..,Merrill Lynch If Anybody That Can Find The $$$$$$ This Guy Can!!!!
""Mr.Cadwell Very Successful Business Man Players Co-Founded Cadwell Laboratories Privately Owned Business In 1979 And Serves As The President Till This Day....Very Savvy Business Mind Indeed!!
Visit Mr. Cadwell's Website Here Players
""Mr.Clement With His Influence Has Already Had Successful FDA Clearance With His Atrial Fibrillation Monitor, And As The CEO Of Two Very Successful Business's.., We Are Very Lucky To Have This Guy On The Board Players!
Advisory Boards:
Dr. Pressman is Professor and Chairman of the S. Mark Taper Foundation Imaging Center and Department, and Chief of the Section of Neuroradiology and Head and Neck Radiology at Cedars-Sinai Medical Center, located in Los Angeles, Ca.
Dr. Pressman is a past President of The American College of Radiology, the Western Neuroradiological Society, as well as past President of the California Radiological Society. Currently he is a member of the American Society of Neuroradiology and the American Society of Pediatric Neuroradiology.
Dr. Pressman earned his medical degree Cum Laude from Harvard Medical School after graduating Summa Cum Laude from Dartmouth College. After a surgical internship at Harvard's Peter Bent Brigham Hospital in Boston, he completed a diagnostic radiology residency at Columbia-Presbyterian Medical Center in New York and a Neuroradiology fellowship at George Washington University Hospital. During this period, he wrote many original papers for Computer Tomography(CT).
"I am delighted to be appointed to Chair the newly formed Medical Advisory Board (MAB) for AMIC. I anticipate rapid expansion of our MAB, initially focusing on the potential for the Company's brachytherapy products," said Pressman.
James C. Katzaroff, CEO of AMIC, stated, "It is with great pleasure I welcome Dr. Pressman's guidance in assisting the Company to enter the commercial marketplace with its therapeutic products. As AMIC expands beyond the distribution and the production of stable and diagnostic radioisotopes, to the manufacturing of therapeutic products with AMIC's own product line, Dr. Pressman will be instrumental in providing a nationally-recognized practitioner's perspective and expertise that will enable the company to meet the growing needs of a dynamic nuclear medicine marketplace."
"" Mr.Fisher Is The Isotope GURU"..,Holds Several Patents Including Patents Licensed By AMIC For It's Brachytherapy Products...,Very Knowledgeable In The Isotope Field Of Technology!!!!.,& Finally Mr. Waltar Who By All Rights Holds The Key To ADMD He Has Ties With India & China, And Will Be Instrumental In Bringing The Y-90 RadioGel™ Device To Market Players!!!!!
Research & Development:
Does Nuclear Medicine Save Lives?
Yes! More than 20 million Americans benefit each year from nuclear medicine procedures used to diagnose and treat a wide variety of diseases. The use of radiation in these procedures— with low risks—offers a safe and cost-effective means to provide doctors with information that would otherwise require exploratory surgery, necessitate more costly and invasive procedures or simply be unavailable. The risks of not performing a needed medical exam are usually much greater than the risks of the radiation exposures associated with the exam.
Nuclear medicine can be used to:
determine whether or not organs are functioning normally,
show whether the blood supply to the heart is adequate,
detect cancers at an early stage,
determine the extent of cancer and assess the response of cancer to treatment,
discover whether the heart can pump blood adequately,
identify abnormal brain lesions without exploratory surgery,
detect whether the brain is receiving an adequate blood supply and if brain cells are functioning or not,
check whether or not kidneys are functioning normally and whether the stomach is emptying properly,
ascertain lung function and bone density and
locate a bone fracture before it can be seen on an X-ray.
Brachytherapy:
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion. It is estimated that the U.S. market represents approximately half of the global market. AMIC believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers. The 2013 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer and 31,000 liver cancer.
AMIC’s Brachytherapy Products
AMIC has exclusively licensed Yttrium-90 (Y-90) polymer composite technology from *Battelle Memorial Institute, developed at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers.
Subject to receipt of all required regulatory approvals from the FDA in the United States and analogous regulators outside of the United States, AMIC plans to introduce a new Y-90-based brachytherapy product line for a range of applications for the delivery of a prescribed dose of radiation to a target site.
•Y-90 RadioGel™ device - combines Y-90 particles with a polymer carrier that may be injected directly into the tumor.
•Y-90 Fast-Resorbable Polymer Seeds - Y-90 contained within a polymer seed, as opposed to metal or glass. This product would be used in place of treating cancers with currently marketed titanium or glass seeds.
•Y-90 Polymer Topical Paste – designed to be applied directly to tissue surfaces after surgical tumor removals (also referred to as “resections”) to treat residual tumor cells..
Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, AMIC believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:
•Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.
•Half Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.
•Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, AMIC’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.
•No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. AMIC’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.
•Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. AMIC’s brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. The Yttrium-90 beta-emissions travel only a short distance and has a short half life of 2.7 days.
•Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.
Products:
""The Cream Of The Crop Players Yttrium 90 RadioGel™ and Polymer Seeds, Is The Future Of Radioactive Brachytherapy, And Is What We Are Waiting On The FDA To Approve....With Battelle In Our Corner There Should Be No Problem Getting This Done....(More On Battelle In a Moment)
Advanced Medical Isotope Corporation has obtained an exclusive license to eight (8) patents for injectable RadioGel™ technology for use in high-dose radiation therapy. The license was granted by *Battelle pursuant to an option between Battelle and AMIC announced in February 2011.
The Agreement grants AMIC an exclusive license to make, have made, use and sell a RadioGel™ system including an injectable, water-based biodegradable polymer that delivers Yttrium-90 microspheres directly into tumor tissues. The solution warms to body temperature quickly after injection and then polymerizes into a lattice that traps the Yttrium-90 microspheres in place. High-energy beta particles from Yttrium-90 efficiently irradiate cancer cells within the targeted volume but very little radiation escapes. This feature maximizes the overall radiation dose to cancer cells while minimizing radiation exposure and associated side-effects in nearby normal tissues.
The injectable radiogel may also be administered transdermally or intraoperatively when treating solid tumors that cannot be removed safely by surgical excision, such as inoperable liver cancer, brain tumors, head and neck tumors, kidney tumors, and pancreatic cancer. Levels of activity may be accelerated to treat radiation-resistant solid tumors that may not respond well to conventional external-beam therapy.
The injectable radiogel may also be administered transdermally or intraoperatively when treating solid tumors that cannot be removed safely by surgical excision, such as inoperable liver cancer, brain tumors, head and neck tumors, kidney tumors, and pancreatic cancer. Levels of activity may be accelerated to treat radiation-resistant solid tumors that may not respond well to conventional external-beam therapy.
Yttrium-90 is a well-established medical isotope with many applications in cancer treatment. The combination of insoluble Yttrium-90 microspheres and the radiogel carrier offers physicians an opportunity to deliver a safe, effective treatment option at a low cost.
The late Dr. Robert Schenter, AMIC's Former Chief Scientific Officer, stated, "AMIC continues to develop the Yttrium-90 RadioGel™ line with Pacific Northwest National Laboratory, operated by Battelle. We believe that this product optimizes treatment of radiation-resistant tumors in vivo. We expect the RadioGel™ to become a therapeutic agent that provides physicians with the ability to effectively treat tumors that cannot be removed surgically or that cannot be treated by any other means."
According to AMIC the primary advantages of licensing these Yttrium-90 radiogels are multifold:
This treatment provides the ability to deliver a highly localized radiation therapy without irradiating nearby normal tissues - thereby achieving desired high therapeutic indices.
We are able to provide dose homogeneity within a solid tumor.
Because Yttrium-90 is a beta emitter, there is improved radiation safety for hospital personnel who prepare and handle the product.
Medical Isotopes:
AMIC is developing innovative approaches to the use, production and distribution of medical isotopes for advanced diagnostic and non-surgical therapeutic applications. A medical isotope is a radioactive substance used in very small quantities for safe, cost-effective medical imaging and treatment of disease.
The cornerstone equipment selected for the AMIC Production Facility is a proton linear accelerator. This proton linear accelerator is designed to replace large and cyclotron systems with significant infrastructure and utility requirements, such as electrical and air-handling, for the production of positron emitting isotopes. Large amounts of fluorine-18, carbon-11, nitrogen-13, and oxygen-15 can be produced for synthesis into compounds used in oncology, cardiology, neurology, and molecular imaging. The radio-labeled glucose analog, FDG, can be synthesized and distributed for use in Positron Emission Tomography. AMIC believes that no other accelerator in North America has sufficient flexibility to produce the full spectrum of PET imaging radioisotopes, as well as other high-demand isotopes, both short and long lived, for diagnostic and therapeutic applications.
From 2008 through 2013, AMIC manufactured and sold F-18 FDG from its Production Facility in its local region around Kennewick, WA. F-18 is an important isotope in the radiopharmaceutical industry, and is primarily synthesized into fluorodeoxyglucose (FDG) for use in positron emission tomography (PET) scans. FDG is the primary PET imaging isotope. It is used for medical and diagnostic purposes, such as cancer detection, heart imaging, and brain imaging. AMIC’s linear accelerator is capable of producing a variety of isotopes and future manufacturing and sales could expand beyond F-18 FDG. AMIC’s accelerator is currently off-line for maintenance and is expected to resume operations in late 2014.
The FDA has 120 days in which to make a decision, though the period will be extended for any time AMIC requires to respond to FDA requests for additional information.
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion.
AMIC's rights for the newly issued patent arise from its license from Battelle, under which AMIC exclusively licensed technologies developed at Pacific Northwest National Laboratory and the University of Utah for its proposed brachytherapy products. The patent awarded, US 8,821,364 B2, relates to AMIC's brachytherapy seed product and is entitled: Brachytherapy Seed with Fast Dissolving Matrix for Optimal Delivery of Radionuclides to Cancer Tissue. AMIC will support Battelle in further patent protection for additional markets consistent with AMIC's overall global commercialization strategy.
Battelle, has acquired approximately 11% of AMIC’s outstanding Common Stock. Battelle is a leading international science and technology enterprise that explores emerging areas of science and develops and commercializes technology.
""Monster Mega DD ADMD""
Today We Witnessed Another Whale On Bid 26Milly @ .0018 Over 47K This With Other Bids In The Past Getting Filled Over 20Milly a Pop We Can Safely Assume That There's Some Entities Out There That Are Loading Up^ Big Time Behind The Scenes Right Underneath Our Noses Players!...I Can Only Imagine What Will Happen If FDA Approval Hits & These Whales Are Still Out There Lurking Trying To Get In..
It's Going To Be Pandemonium Here On ADMD... I Can See It Know Ask Gapping Up Peeps Chasing ADMD To No End!!...Don't Let This Be YOU""
So With This In Mind Take Your Time & Decipher This Monster DD That's Laid Out In Front Of You & Maybe Then You Willl Come To Your Senses!!!!...>>LMFAO!
""Pimping Hard & Keeping The Game Real""
Corporate Overview:
Advanced Medical Isotope Corporation (AMIC) (ADMD: OTCQB) is a Kennewick, Washington-based late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications. AMIC's focus is on transitioning to full operations upon receipt of FDA clearance for its patented brachytherapy cancer products.
Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. Annual sales of brachytherapy products exceed $1 billion, about half of which are in the United States. AMIC intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though AMIC will evaluate its alternatives before finalizing its plans.
Since 2006, AMIC has been focused on the commercialization of medical isotope technologies. AMIC has explored technologies for the production of medical isotopes and medical applications of isotope technologies including a line of brachytherapy products
incorporating patented technology licensed exclusively to AMIC by Battelle Memorial Institute, developed at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers.
AMIC’s robust intellectual property position includes exclusive rights under 15 patents
that cover manufacturing, processing and applications for medical isotopes.
A prominent team of radiochemists, scientists and engineers, collaborating worldwide
with strategic partners, including national laboratories, universities and private corporations,
lead AMIC’s development efforts. AMIC is proud to have been recognized as a leader in the
development of new isotope technologies by local, state and federal agencies.
Management:
Mr.Katzoroff Is a Financial Guru Players Having This Guy @ The Helm Is Huge PLUS!...& Mr.Jolliff Is The Numbers Guy, He's The One Behind The Scenes Getting The Money We Need To Get The Product To The Market!
Mr.Stevensen The Madd Scientist...This Guy Is a GENIUS"" He'll Be The One Behind The Scenes Bringing New Products To Fruition..He's a Nuclear Pysics Expert!....& Mr.Ludwig, now This Gentlemen Has International Ties Over Seas, So It's Easy To Imagine Who He Can Bring To The Table!!!!!
""Heavy Weight Mr.Su, Now This Guy Here Is The Mastermind Behind The Scenes Of The Isotope R&D Manufacturing...He Works For Pharma GIANTS"" Like Bristol-Myers Squibb..Also Working
As a Senior Scientist For Several Bio-Technology Firms, Including NeoRx, Nycomed-Amersham,And Cellectar, He Developed Various Radiopharmaceuticals, Very Impressive Savvy Scientist Players!!..,& Last But Not Lease,
Mr. Korenko.,Very..,Very Astute Intelligent Man Who Was Educated At One Of The Most Prestigious Colleges In The World ""OXFORD"" He Was Selected As a White House Fellow For The Department Of Defense Reporting To Secretary Cap Weinberger...,So Yes This Guy Has Inside Connection o The Dept Of Health And Human Services Players!!!!!
Board Of Director's:
"" Mr.Spivak What Can I Say Other Than They Call Him The Billion Dollar Man""...,Billions In Acquisitions..,Mergers..,Financing's This Guy Has Worked With Bigg Oil Mobil..,Merrill Lynch If Anybody That Can Find The $$$$$$ This Guy Can!!!!
""Mr.Cadwell Very Successful Business Man Players Co-Founded Cadwell Laboratories Privately Owned Business In 1979 And Serves As The President Till This Day....Very Savvy Business Mind Indeed!!
Visit Mr. Cadwell's Website Here Players
""Mr.Clement With His Influence Has Already Had Successful FDA Clearance With His Atrial Fibrillation Monitor, And As The CEO Of Two Very Successful Business's.., We Are Very Lucky To Have This Guy On The Board Players!
Advisory Boards:
Dr. Pressman is Professor and Chairman of the S. Mark Taper Foundation Imaging Center and Department, and Chief of the Section of Neuroradiology and Head and Neck Radiology at Cedars-Sinai Medical Center, located in Los Angeles, Ca.
Dr. Pressman is a past President of The American College of Radiology, the Western Neuroradiological Society, as well as past President of the California Radiological Society. Currently he is a member of the American Society of Neuroradiology and the American Society of Pediatric Neuroradiology.
Dr. Pressman earned his medical degree Cum Laude from Harvard Medical School after graduating Summa Cum Laude from Dartmouth College. After a surgical internship at Harvard's Peter Bent Brigham Hospital in Boston, he completed a diagnostic radiology residency at Columbia-Presbyterian Medical Center in New York and a Neuroradiology fellowship at George Washington University Hospital. During this period, he wrote many original papers for Computer Tomography(CT).
"I am delighted to be appointed to Chair the newly formed Medical Advisory Board (MAB) for AMIC. I anticipate rapid expansion of our MAB, initially focusing on the potential for the Company's brachytherapy products," said Pressman.
James C. Katzaroff, CEO of AMIC, stated, "It is with great pleasure I welcome Dr. Pressman's guidance in assisting the Company to enter the commercial marketplace with its therapeutic products. As AMIC expands beyond the distribution and the production of stable and diagnostic radioisotopes, to the manufacturing of therapeutic products with AMIC's own product line, Dr. Pressman will be instrumental in providing a nationally-recognized practitioner's perspective and expertise that will enable the company to meet the growing needs of a dynamic nuclear medicine marketplace."
"" Mr.Fisher Is The Isotope GURU"..,Holds Several Patents Including Patents Licensed By AMIC For It's Brachytherapy Products...,Very Knowledgeable In The Isotope Field Of Technology!!!!.,& Finally Mr. Waltar Who By All Rights Holds The Key To ADMD He Has Ties With India & China, And Will Be Instrumental In Bringing The Y-90 RadioGel™ Device To Market Players!!!!!
Research & Development:
Does Nuclear Medicine Save Lives?
Yes! More than 20 million Americans benefit each year from nuclear medicine procedures used to diagnose and treat a wide variety of diseases. The use of radiation in these procedures— with low risks—offers a safe and cost-effective means to provide doctors with information that would otherwise require exploratory surgery, necessitate more costly and invasive procedures or simply be unavailable. The risks of not performing a needed medical exam are usually much greater than the risks of the radiation exposures associated with the exam.
Nuclear medicine can be used to:
determine whether or not organs are functioning normally,
show whether the blood supply to the heart is adequate,
detect cancers at an early stage,
determine the extent of cancer and assess the response of cancer to treatment,
discover whether the heart can pump blood adequately,
identify abnormal brain lesions without exploratory surgery,
detect whether the brain is receiving an adequate blood supply and if brain cells are functioning or not,
check whether or not kidneys are functioning normally and whether the stomach is emptying properly,
ascertain lung function and bone density and
locate a bone fracture before it can be seen on an X-ray.
Brachytherapy:
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion. It is estimated that the U.S. market represents approximately half of the global market. AMIC believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers. The 2013 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer and 31,000 liver cancer.
AMIC’s Brachytherapy Products
AMIC has exclusively licensed Yttrium-90 (Y-90) polymer composite technology from *Battelle Memorial Institute, developed at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers.
Subject to receipt of all required regulatory approvals from the FDA in the United States and analogous regulators outside of the United States, AMIC plans to introduce a new Y-90-based brachytherapy product line for a range of applications for the delivery of a prescribed dose of radiation to a target site.
•Y-90 RadioGel™ device - combines Y-90 particles with a polymer carrier that may be injected directly into the tumor.
•Y-90 Fast-Resorbable Polymer Seeds - Y-90 contained within a polymer seed, as opposed to metal or glass. This product would be used in place of treating cancers with currently marketed titanium or glass seeds.
•Y-90 Polymer Topical Paste – designed to be applied directly to tissue surfaces after surgical tumor removals (also referred to as “resections”) to treat residual tumor cells..
Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, AMIC believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:
•Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.
•Half Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.
•Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, AMIC’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.
•No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. AMIC’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.
•Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. AMIC’s brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. The Yttrium-90 beta-emissions travel only a short distance and has a short half life of 2.7 days.
•Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.
Products:
""The Cream Of The Crop Players Yttrium 90 RadioGel™ and Polymer Seeds, Is The Future Of Radioactive Brachytherapy, And Is What We Are Waiting On The FDA To Approve....With Battelle In Our Corner There Should Be No Problem Getting This Done....(More On Battelle In a Moment)
Advanced Medical Isotope Corporation has obtained an exclusive license to eight (8) patents for injectable RadioGel™ technology for use in high-dose radiation therapy. The license was granted by *Battelle pursuant to an option between Battelle and AMIC announced in February 2011.
The Agreement grants AMIC an exclusive license to make, have made, use and sell a RadioGel™ system including an injectable, water-based biodegradable polymer that delivers Yttrium-90 microspheres directly into tumor tissues. The solution warms to body temperature quickly after injection and then polymerizes into a lattice that traps the Yttrium-90 microspheres in place. High-energy beta particles from Yttrium-90 efficiently irradiate cancer cells within the targeted volume but very little radiation escapes. This feature maximizes the overall radiation dose to cancer cells while minimizing radiation exposure and associated side-effects in nearby normal tissues.
The injectable radiogel may also be administered transdermally or intraoperatively when treating solid tumors that cannot be removed safely by surgical excision, such as inoperable liver cancer, brain tumors, head and neck tumors, kidney tumors, and pancreatic cancer. Levels of activity may be accelerated to treat radiation-resistant solid tumors that may not respond well to conventional external-beam therapy.
The injectable radiogel may also be administered transdermally or intraoperatively when treating solid tumors that cannot be removed safely by surgical excision, such as inoperable liver cancer, brain tumors, head and neck tumors, kidney tumors, and pancreatic cancer. Levels of activity may be accelerated to treat radiation-resistant solid tumors that may not respond well to conventional external-beam therapy.
Yttrium-90 is a well-established medical isotope with many applications in cancer treatment. The combination of insoluble Yttrium-90 microspheres and the radiogel carrier offers physicians an opportunity to deliver a safe, effective treatment option at a low cost.
The late Dr. Robert Schenter, AMIC's Former Chief Scientific Officer, stated, "AMIC continues to develop the Yttrium-90 RadioGel™ line with Pacific Northwest National Laboratory, operated by Battelle. We believe that this product optimizes treatment of radiation-resistant tumors in vivo. We expect the RadioGel™ to become a therapeutic agent that provides physicians with the ability to effectively treat tumors that cannot be removed surgically or that cannot be treated by any other means."
According to AMIC the primary advantages of licensing these Yttrium-90 radiogels are multifold:
This treatment provides the ability to deliver a highly localized radiation therapy without irradiating nearby normal tissues - thereby achieving desired high therapeutic indices.
We are able to provide dose homogeneity within a solid tumor.
Because Yttrium-90 is a beta emitter, there is improved radiation safety for hospital personnel who prepare and handle the product.
Medical Isotopes:
AMIC is developing innovative approaches to the use, production and distribution of medical isotopes for advanced diagnostic and non-surgical therapeutic applications. A medical isotope is a radioactive substance used in very small quantities for safe, cost-effective medical imaging and treatment of disease.
The cornerstone equipment selected for the AMIC Production Facility is a proton linear accelerator. This proton linear accelerator is designed to replace large and cyclotron systems with significant infrastructure and utility requirements, such as electrical and air-handling, for the production of positron emitting isotopes. Large amounts of fluorine-18, carbon-11, nitrogen-13, and oxygen-15 can be produced for synthesis into compounds used in oncology, cardiology, neurology, and molecular imaging. The radio-labeled glucose analog, FDG, can be synthesized and distributed for use in Positron Emission Tomography. AMIC believes that no other accelerator in North America has sufficient flexibility to produce the full spectrum of PET imaging radioisotopes, as well as other high-demand isotopes, both short and long lived, for diagnostic and therapeutic applications.
From 2008 through 2013, AMIC manufactured and sold F-18 FDG from its Production Facility in its local region around Kennewick, WA. F-18 is an important isotope in the radiopharmaceutical industry, and is primarily synthesized into fluorodeoxyglucose (FDG) for use in positron emission tomography (PET) scans. FDG is the primary PET imaging isotope. It is used for medical and diagnostic purposes, such as cancer detection, heart imaging, and brain imaging. AMIC’s linear accelerator is capable of producing a variety of isotopes and future manufacturing and sales could expand beyond F-18 FDG. AMIC’s accelerator is currently off-line for maintenance and is expected to resume operations in late 2014.
The FDA has 120 days in which to make a decision, though the period will be extended for any time AMIC requires to respond to FDA requests for additional information.
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion.
AMIC's rights for the newly issued patent arise from its license from Battelle, under which AMIC exclusively licensed technologies developed at Pacific Northwest National Laboratory and the University of Utah for its proposed brachytherapy products. The patent awarded, US 8,821,364 B2, relates to AMIC's brachytherapy seed product and is entitled: Brachytherapy Seed with Fast Dissolving Matrix for Optimal Delivery of Radionuclides to Cancer Tissue. AMIC will support Battelle in further patent protection for additional markets consistent with AMIC's overall global commercialization strategy.
Battelle, has acquired approximately 11% of AMIC’s outstanding Common Stock. Battelle is a leading international science and technology enterprise that explores emerging areas of science and develops and commercializes technology.
Thanks Bro!.....I'm Just Trying To Get Folks To Understand The Gravity Of ADMD & Want They Have Invested In Here....I've Been Around The Markets For Many Years And I've Only Seen A Handful Of Actual Certified Pinkies That Qualify For Investing In & This Is One Of Them....
ADMD Is On The Cusp Of Breaking Big & The Potential Of How High This Can Go Is ENORMOUS""...I've Been Preaching About .05 Before News Even Breaks, And This Assessment Hasn't Changed One Iota....Given The Fact I Bare Witness Of The Absurd Accumulation That Has Been Taken Place Here Over The Course Of About a Month Is Enough To Choke a ""BULL""!!!!
This Ingredient Alone Is Enough To Catapult ADMD Well Into The Pennies Before Any Of Us May Think.....Imagine a 200Milly Volume Day Here With The Accum/Dist Level Where It Is Now Over 1.2B & The Float Only 1.1B This Is a Very Potent Security Right Now Waiting To EXPLODE!!!
Next Week Watch The Bid Closely & You Will See How This Accumulation Drums Keeps Beating On..,&..,On Until Finally The Ask Will Start To Get Pounded,Because There Will Be No More Shares On The Bid To Be Had,And This Will Be The Start To The March To SILVER""...>>>>>>> Mark It!
Thanks Bro.......#74 For You....PVSP Players Looking.....Doing DD!
Thanks Bro......ADMD Looking To Gain Some Higher Ground This Week...
#1390 For You~
Read The Top Stinkie On ADMD.....
Me Likey......Nice~
ADMD
""Players Lurking~~~~~~~~~~~
That's The Key Word Coltblue ""BATTELLE"" They Already Own Over 10% Of ADMD And They Do Have ALL The Resources ADMD Needs To Get The Y-90 RadioGel™ Device To Market, So All The Pieces Are In Place All We Need Is The FDA Approval & It's Pandemonium Time My Friend!!!
I Wholeheartedly Agree 100% Bro""......ADMD Falls In The Same Category As Those You Just Mentioned Without a DOUBT""
""Indeed My Friend ADMD Will Start To Move Fast N Furious""
""Monster Mega DD ADMD""
Today We Witnessed Another Whale On Bid 26Milly @ .0018 Over 47K This With Other Bids In The Past Getting Filled Over 20Milly a Pop We Can Safely Assume That There's Some Entities Out There That Are Loading Up^ Big Time Behind The Scenes Right Underneath Our Noses Players!...I Can Only Imagine What Will Happen If FDA Approval Hits & These Whales Are Still Out There Lurking Trying To Get In..
It's Going To Be Pandemonium Here On ADMD... I Can See It Know Ask Gapping Up Peeps Chasing ADMD To No End!!...Don't Let This Be YOU""
So With This In Mind Take Your Time & Decipher This Monster DD That's Laid Out In Front Of You & Maybe Then You Willl Come To Your Senses!!!!...>>LMFAO!
""Pimping Hard & Keeping The Game Real""
Corporate Overview:
Advanced Medical Isotope Corporation (AMIC) (ADMD: OTCQB) is a Kennewick, Washington-based late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications. AMIC's focus is on transitioning to full operations upon receipt of FDA clearance for its patented brachytherapy cancer products.
Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. Annual sales of brachytherapy products exceed $1 billion, about half of which are in the United States. AMIC intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though AMIC will evaluate its alternatives before finalizing its plans.
Since 2006, AMIC has been focused on the commercialization of medical isotope technologies. AMIC has explored technologies for the production of medical isotopes and medical applications of isotope technologies including a line of brachytherapy products
incorporating patented technology licensed exclusively to AMIC by Battelle Memorial Institute, developed at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers.
AMIC’s robust intellectual property position includes exclusive rights under 15 patents
that cover manufacturing, processing and applications for medical isotopes.
A prominent team of radiochemists, scientists and engineers, collaborating worldwide
with strategic partners, including national laboratories, universities and private corporations,
lead AMIC’s development efforts. AMIC is proud to have been recognized as a leader in the
development of new isotope technologies by local, state and federal agencies.
Management:
Mr.Katzoroff Is a Financial Guru Players Having This Guy @ The Helm Is Huge PLUS!...& Mr.Jolliff Is The Numbers Guy, He's The One Behind The Scenes Getting The Money We Need To Get The Product To The Market!
Mr.Stevensen The Madd Scientist...This Guy Is a GENIUS"" He'll Be The One Behind The Scenes Bringing New Products To Fruition..He's a Nuclear Pysics Expert!....& Mr.Ludwig, now This Gentlemen Has International Ties Over Seas, So It's Easy To Imagine Who He Can Bring To The Table!!!!!
""Heavy Weight Mr.Su, Now This Guy Here Is The Mastermind Behind The Scenes Of The Isotope R&D Manufacturing...He Works For Pharma GIANTS"" Like Bristol-Myers Squibb..Also Working
As a Senior Scientist For Several Bio-Technology Firms, Including NeoRx, Nycomed-Amersham,And Cellectar, He Developed Various Radiopharmaceuticals, Very Impressive Savvy Scientist Players!!..,& Last But Not Lease,
Mr. Korenko.,Very..,Very Astute Intelligent Man Who Was Educated At One Of The Most Prestigious Colleges In The World ""OXFORD"" He Was Selected As a White House Fellow For The Department Of Defense Reporting To Secretary Cap Weinberger...,So Yes This Guy Has Inside Connection o The Dept Of Health And Human Services Players!!!!!
Board Of Director's:
"" Mr.Spivak What Can I Say Other Than They Call Him The Billion Dollar Man""...,Billions In Acquisitions..,Mergers..,Financing's This Guy Has Worked With Bigg Oil Mobil..,Merrill Lynch If Anybody That Can Find The $$$$$$ This Guy Can!!!!
""Mr.Cadwell Very Successful Business Man Players Co-Founded Cadwell Laboratories Privately Owned Business In 1979 And Serves As The President Till This Day....Very Savvy Business Mind Indeed!!
Visit Mr. Cadwell's Website Here Players
""Mr.Clement With His Influence Has Already Had Successful FDA Clearance With His Atrial Fibrillation Monitor, And As The CEO Of Two Very Successful Business's.., We Are Very Lucky To Have This Guy On The Board Players!
Advisory Boards:
Dr. Pressman is Professor and Chairman of the S. Mark Taper Foundation Imaging Center and Department, and Chief of the Section of Neuroradiology and Head and Neck Radiology at Cedars-Sinai Medical Center, located in Los Angeles, Ca.
Dr. Pressman is a past President of The American College of Radiology, the Western Neuroradiological Society, as well as past President of the California Radiological Society. Currently he is a member of the American Society of Neuroradiology and the American Society of Pediatric Neuroradiology.
Dr. Pressman earned his medical degree Cum Laude from Harvard Medical School after graduating Summa Cum Laude from Dartmouth College. After a surgical internship at Harvard's Peter Bent Brigham Hospital in Boston, he completed a diagnostic radiology residency at Columbia-Presbyterian Medical Center in New York and a Neuroradiology fellowship at George Washington University Hospital. During this period, he wrote many original papers for Computer Tomography(CT).
"I am delighted to be appointed to Chair the newly formed Medical Advisory Board (MAB) for AMIC. I anticipate rapid expansion of our MAB, initially focusing on the potential for the Company's brachytherapy products," said Pressman.
James C. Katzaroff, CEO of AMIC, stated, "It is with great pleasure I welcome Dr. Pressman's guidance in assisting the Company to enter the commercial marketplace with its therapeutic products. As AMIC expands beyond the distribution and the production of stable and diagnostic radioisotopes, to the manufacturing of therapeutic products with AMIC's own product line, Dr. Pressman will be instrumental in providing a nationally-recognized practitioner's perspective and expertise that will enable the company to meet the growing needs of a dynamic nuclear medicine marketplace."
"" Mr.Fisher Is The Isotope GURU"..,Holds Several Patents Including Patents Licensed By AMIC For It's Brachytherapy Products...,Very Knowledgeable In The Isotope Field Of Technology!!!!.,& Finally Mr. Waltar Who By All Rights Holds The Key To ADMD He Has Ties With India & China, And Will Be Instrumental In Bringing The Y-90 RadioGel™ Device To Market Players!!!!!
Research & Development:
Does Nuclear Medicine Save Lives?
Yes! More than 20 million Americans benefit each year from nuclear medicine procedures used to diagnose and treat a wide variety of diseases. The use of radiation in these procedures— with low risks—offers a safe and cost-effective means to provide doctors with information that would otherwise require exploratory surgery, necessitate more costly and invasive procedures or simply be unavailable. The risks of not performing a needed medical exam are usually much greater than the risks of the radiation exposures associated with the exam.
Nuclear medicine can be used to:
determine whether or not organs are functioning normally,
show whether the blood supply to the heart is adequate,
detect cancers at an early stage,
determine the extent of cancer and assess the response of cancer to treatment,
discover whether the heart can pump blood adequately,
identify abnormal brain lesions without exploratory surgery,
detect whether the brain is receiving an adequate blood supply and if brain cells are functioning or not,
check whether or not kidneys are functioning normally and whether the stomach is emptying properly,
ascertain lung function and bone density and
locate a bone fracture before it can be seen on an X-ray.
Brachytherapy:
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion. It is estimated that the U.S. market represents approximately half of the global market. AMIC believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers. The 2013 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer and 31,000 liver cancer.
AMIC’s Brachytherapy Products
AMIC has exclusively licensed Yttrium-90 (Y-90) polymer composite technology from *Battelle Memorial Institute, developed at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers.
Subject to receipt of all required regulatory approvals from the FDA in the United States and analogous regulators outside of the United States, AMIC plans to introduce a new Y-90-based brachytherapy product line for a range of applications for the delivery of a prescribed dose of radiation to a target site.
•Y-90 RadioGel™ device - combines Y-90 particles with a polymer carrier that may be injected directly into the tumor.
•Y-90 Fast-Resorbable Polymer Seeds - Y-90 contained within a polymer seed, as opposed to metal or glass. This product would be used in place of treating cancers with currently marketed titanium or glass seeds.
•Y-90 Polymer Topical Paste – designed to be applied directly to tissue surfaces after surgical tumor removals (also referred to as “resections”) to treat residual tumor cells..
Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, AMIC believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:
•Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.
•Half Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.
•Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, AMIC’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.
•No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. AMIC’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.
•Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. AMIC’s brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. The Yttrium-90 beta-emissions travel only a short distance and has a short half life of 2.7 days.
•Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.
Products:
""The Cream Of The Crop Players Yttrium 90 RadioGel™ and Polymer Seeds, Is The Future Of Radioactive Brachytherapy, And Is What We Are Waiting On The FDA To Approve....With Battelle In Our Corner There Should Be No Problem Getting This Done....(More On Battelle In a Moment)
Advanced Medical Isotope Corporation has obtained an exclusive license to eight (8) patents for injectable RadioGel™ technology for use in high-dose radiation therapy. The license was granted by *Battelle pursuant to an option between Battelle and AMIC announced in February 2011.
The Agreement grants AMIC an exclusive license to make, have made, use and sell a RadioGel™ system including an injectable, water-based biodegradable polymer that delivers Yttrium-90 microspheres directly into tumor tissues. The solution warms to body temperature quickly after injection and then polymerizes into a lattice that traps the Yttrium-90 microspheres in place. High-energy beta particles from Yttrium-90 efficiently irradiate cancer cells within the targeted volume but very little radiation escapes. This feature maximizes the overall radiation dose to cancer cells while minimizing radiation exposure and associated side-effects in nearby normal tissues.
The injectable radiogel may also be administered transdermally or intraoperatively when treating solid tumors that cannot be removed safely by surgical excision, such as inoperable liver cancer, brain tumors, head and neck tumors, kidney tumors, and pancreatic cancer. Levels of activity may be accelerated to treat radiation-resistant solid tumors that may not respond well to conventional external-beam therapy.
The injectable radiogel may also be administered transdermally or intraoperatively when treating solid tumors that cannot be removed safely by surgical excision, such as inoperable liver cancer, brain tumors, head and neck tumors, kidney tumors, and pancreatic cancer. Levels of activity may be accelerated to treat radiation-resistant solid tumors that may not respond well to conventional external-beam therapy.
Yttrium-90 is a well-established medical isotope with many applications in cancer treatment. The combination of insoluble Yttrium-90 microspheres and the radiogel carrier offers physicians an opportunity to deliver a safe, effective treatment option at a low cost.
The late Dr. Robert Schenter, AMIC's Former Chief Scientific Officer, stated, "AMIC continues to develop the Yttrium-90 RadioGel™ line with Pacific Northwest National Laboratory, operated by Battelle. We believe that this product optimizes treatment of radiation-resistant tumors in vivo. We expect the RadioGel™ to become a therapeutic agent that provides physicians with the ability to effectively treat tumors that cannot be removed surgically or that cannot be treated by any other means."
According to AMIC the primary advantages of licensing these Yttrium-90 radiogels are multifold:
This treatment provides the ability to deliver a highly localized radiation therapy without irradiating nearby normal tissues - thereby achieving desired high therapeutic indices.
We are able to provide dose homogeneity within a solid tumor.
Because Yttrium-90 is a beta emitter, there is improved radiation safety for hospital personnel who prepare and handle the product.
Medical Isotopes:
AMIC is developing innovative approaches to the use, production and distribution of medical isotopes for advanced diagnostic and non-surgical therapeutic applications. A medical isotope is a radioactive substance used in very small quantities for safe, cost-effective medical imaging and treatment of disease.
The cornerstone equipment selected for the AMIC Production Facility is a proton linear accelerator. This proton linear accelerator is designed to replace large and cyclotron systems with significant infrastructure and utility requirements, such as electrical and air-handling, for the production of positron emitting isotopes. Large amounts of fluorine-18, carbon-11, nitrogen-13, and oxygen-15 can be produced for synthesis into compounds used in oncology, cardiology, neurology, and molecular imaging. The radio-labeled glucose analog, FDG, can be synthesized and distributed for use in Positron Emission Tomography. AMIC believes that no other accelerator in North America has sufficient flexibility to produce the full spectrum of PET imaging radioisotopes, as well as other high-demand isotopes, both short and long lived, for diagnostic and therapeutic applications.
From 2008 through 2013, AMIC manufactured and sold F-18 FDG from its Production Facility in its local region around Kennewick, WA. F-18 is an important isotope in the radiopharmaceutical industry, and is primarily synthesized into fluorodeoxyglucose (FDG) for use in positron emission tomography (PET) scans. FDG is the primary PET imaging isotope. It is used for medical and diagnostic purposes, such as cancer detection, heart imaging, and brain imaging. AMIC’s linear accelerator is capable of producing a variety of isotopes and future manufacturing and sales could expand beyond F-18 FDG. AMIC’s accelerator is currently off-line for maintenance and is expected to resume operations in late 2014.
The FDA has 120 days in which to make a decision, though the period will be extended for any time AMIC requires to respond to FDA requests for additional information.
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion.
AMIC's rights for the newly issued patent arise from its license from Battelle, under which AMIC exclusively licensed technologies developed at Pacific Northwest National Laboratory and the University of Utah for its proposed brachytherapy products. The patent awarded, US 8,821,364 B2, relates to AMIC's brachytherapy seed product and is entitled: Brachytherapy Seed with Fast Dissolving Matrix for Optimal Delivery of Radionuclides to Cancer Tissue. AMIC will support Battelle in further patent protection for additional markets consistent with AMIC's overall global commercialization strategy.
Battelle, has acquired approximately 11% of AMIC’s outstanding Common Stock. Battelle is a leading international science and technology enterprise that explores emerging areas of science and develops and commercializes technology.
""Monster Mega DD ADMD""
Today We Witnessed Another Whale On Bid 26Milly @ .0018 Over 47K This With Other Bids In The Past Getting Filled Over 20Milly a Pop We Can Safely Assume That There's Some Entities Out There That Are Loading Up^ Big Time Behind The Scenes Right Underneath Our Noses Players!...I Can Only Imagine What Will Happen If FDA Approval Hits & These Whales Are Still Out There Lurking Trying To Get In..
It's Going To Be Pandemonium Here On ADMD... I Can See It Know Ask Gapping Up Peeps Chasing ADMD To No End!!...Don't Let This Be YOU""
So With This In Mind Take Your Time & Decipher This Monster DD That's Laid Out In Front Of You & Maybe Then You Willl Come To Your Senses!!!!...>>LMFAO!
""Pimping Hard & Keeping The Game Real""
Corporate Overview:
Advanced Medical Isotope Corporation (AMIC) (ADMD: OTCQB) is a Kennewick, Washington-based late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications. AMIC's focus is on transitioning to full operations upon receipt of FDA clearance for its patented brachytherapy cancer products.
Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. Annual sales of brachytherapy products exceed $1 billion, about half of which are in the United States. AMIC intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though AMIC will evaluate its alternatives before finalizing its plans.
Since 2006, AMIC has been focused on the commercialization of medical isotope technologies. AMIC has explored technologies for the production of medical isotopes and medical applications of isotope technologies including a line of brachytherapy products
incorporating patented technology licensed exclusively to AMIC by Battelle Memorial Institute, developed at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers.
AMIC’s robust intellectual property position includes exclusive rights under 15 patents
that cover manufacturing, processing and applications for medical isotopes.
A prominent team of radiochemists, scientists and engineers, collaborating worldwide
with strategic partners, including national laboratories, universities and private corporations,
lead AMIC’s development efforts. AMIC is proud to have been recognized as a leader in the
development of new isotope technologies by local, state and federal agencies.
Management:
Mr.Katzoroff Is a Financial Guru Players Having This Guy @ The Helm Is Huge PLUS!...& Mr.Jolliff Is The Numbers Guy, He's The One Behind The Scenes Getting The Money We Need To Get The Product To The Market!
Mr.Stevensen The Madd Scientist...This Guy Is a GENIUS"" He'll Be The One Behind The Scenes Bringing New Products To Fruition..He's a Nuclear Pysics Expert!....& Mr.Ludwig, now This Gentlemen Has International Ties Over Seas, So It's Easy To Imagine Who He Can Bring To The Table!!!!!
""Heavy Weight Mr.Su, Now This Guy Here Is The Mastermind Behind The Scenes Of The Isotope R&D Manufacturing...He Works For Pharma GIANTS"" Like Bristol-Myers Squibb..Also Working
As a Senior Scientist For Several Bio-Technology Firms, Including NeoRx, Nycomed-Amersham,And Cellectar, He Developed Various Radiopharmaceuticals, Very Impressive Savvy Scientist Players!!..,& Last But Not Lease,
Mr. Korenko.,Very..,Very Astute Intelligent Man Who Was Educated At One Of The Most Prestigious Colleges In The World ""OXFORD"" He Was Selected As a White House Fellow For The Department Of Defense Reporting To Secretary Cap Weinberger...,So Yes This Guy Has Inside Connection o The Dept Of Health And Human Services Players!!!!!
Board Of Director's:
"" Mr.Spivak What Can I Say Other Than They Call Him The Billion Dollar Man""...,Billions In Acquisitions..,Mergers..,Financing's This Guy Has Worked With Bigg Oil Mobil..,Merrill Lynch If Anybody That Can Find The $$$$$$ This Guy Can!!!!
""Mr.Cadwell Very Successful Business Man Players Co-Founded Cadwell Laboratories Privately Owned Business In 1979 And Serves As The President Till This Day....Very Savvy Business Mind Indeed!!
Visit Mr. Cadwell's Website Here Players
""Mr.Clement With His Influence Has Already Had Successful FDA Clearance With His Atrial Fibrillation Monitor, And As The CEO Of Two Very Successful Business's.., We Are Very Lucky To Have This Guy On The Board Players!
Advisory Boards:
Dr. Pressman is Professor and Chairman of the S. Mark Taper Foundation Imaging Center and Department, and Chief of the Section of Neuroradiology and Head and Neck Radiology at Cedars-Sinai Medical Center, located in Los Angeles, Ca.
Dr. Pressman is a past President of The American College of Radiology, the Western Neuroradiological Society, as well as past President of the California Radiological Society. Currently he is a member of the American Society of Neuroradiology and the American Society of Pediatric Neuroradiology.
Dr. Pressman earned his medical degree Cum Laude from Harvard Medical School after graduating Summa Cum Laude from Dartmouth College. After a surgical internship at Harvard's Peter Bent Brigham Hospital in Boston, he completed a diagnostic radiology residency at Columbia-Presbyterian Medical Center in New York and a Neuroradiology fellowship at George Washington University Hospital. During this period, he wrote many original papers for Computer Tomography(CT).
"I am delighted to be appointed to Chair the newly formed Medical Advisory Board (MAB) for AMIC. I anticipate rapid expansion of our MAB, initially focusing on the potential for the Company's brachytherapy products," said Pressman.
James C. Katzaroff, CEO of AMIC, stated, "It is with great pleasure I welcome Dr. Pressman's guidance in assisting the Company to enter the commercial marketplace with its therapeutic products. As AMIC expands beyond the distribution and the production of stable and diagnostic radioisotopes, to the manufacturing of therapeutic products with AMIC's own product line, Dr. Pressman will be instrumental in providing a nationally-recognized practitioner's perspective and expertise that will enable the company to meet the growing needs of a dynamic nuclear medicine marketplace."
"" Mr.Fisher Is The Isotope GURU"..,Holds Several Patents Including Patents Licensed By AMIC For It's Brachytherapy Products...,Very Knowledgeable In The Isotope Field Of Technology!!!!.,& Finally Mr. Waltar Who By All Rights Holds The Key To ADMD He Has Ties With India & China, And Will Be Instrumental In Bringing The Y-90 RadioGel™ Device To Market Players!!!!!
Research & Development:
Does Nuclear Medicine Save Lives?
Yes! More than 20 million Americans benefit each year from nuclear medicine procedures used to diagnose and treat a wide variety of diseases. The use of radiation in these procedures— with low risks—offers a safe and cost-effective means to provide doctors with information that would otherwise require exploratory surgery, necessitate more costly and invasive procedures or simply be unavailable. The risks of not performing a needed medical exam are usually much greater than the risks of the radiation exposures associated with the exam.
Nuclear medicine can be used to:
determine whether or not organs are functioning normally,
show whether the blood supply to the heart is adequate,
detect cancers at an early stage,
determine the extent of cancer and assess the response of cancer to treatment,
discover whether the heart can pump blood adequately,
identify abnormal brain lesions without exploratory surgery,
detect whether the brain is receiving an adequate blood supply and if brain cells are functioning or not,
check whether or not kidneys are functioning normally and whether the stomach is emptying properly,
ascertain lung function and bone density and
locate a bone fracture before it can be seen on an X-ray.
Brachytherapy:
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion. It is estimated that the U.S. market represents approximately half of the global market. AMIC believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers. The 2013 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer and 31,000 liver cancer.
AMIC’s Brachytherapy Products
AMIC has exclusively licensed Yttrium-90 (Y-90) polymer composite technology from *Battelle Memorial Institute, developed at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers.
Subject to receipt of all required regulatory approvals from the FDA in the United States and analogous regulators outside of the United States, AMIC plans to introduce a new Y-90-based brachytherapy product line for a range of applications for the delivery of a prescribed dose of radiation to a target site.
•Y-90 RadioGel™ device - combines Y-90 particles with a polymer carrier that may be injected directly into the tumor.
•Y-90 Fast-Resorbable Polymer Seeds - Y-90 contained within a polymer seed, as opposed to metal or glass. This product would be used in place of treating cancers with currently marketed titanium or glass seeds.
•Y-90 Polymer Topical Paste – designed to be applied directly to tissue surfaces after surgical tumor removals (also referred to as “resections”) to treat residual tumor cells..
Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, AMIC believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:
•Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.
•Half Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.
•Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, AMIC’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.
•No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. AMIC’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.
•Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. AMIC’s brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. The Yttrium-90 beta-emissions travel only a short distance and has a short half life of 2.7 days.
•Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.
Products:
""The Cream Of The Crop Players Yttrium 90 RadioGel™ and Polymer Seeds, Is The Future Of Radioactive Brachytherapy, And Is What We Are Waiting On The FDA To Approve....With Battelle In Our Corner There Should Be No Problem Getting This Done....(More On Battelle In a Moment)
Advanced Medical Isotope Corporation has obtained an exclusive license to eight (8) patents for injectable RadioGel™ technology for use in high-dose radiation therapy. The license was granted by *Battelle pursuant to an option between Battelle and AMIC announced in February 2011.
The Agreement grants AMIC an exclusive license to make, have made, use and sell a RadioGel™ system including an injectable, water-based biodegradable polymer that delivers Yttrium-90 microspheres directly into tumor tissues. The solution warms to body temperature quickly after injection and then polymerizes into a lattice that traps the Yttrium-90 microspheres in place. High-energy beta particles from Yttrium-90 efficiently irradiate cancer cells within the targeted volume but very little radiation escapes. This feature maximizes the overall radiation dose to cancer cells while minimizing radiation exposure and associated side-effects in nearby normal tissues.
The injectable radiogel may also be administered transdermally or intraoperatively when treating solid tumors that cannot be removed safely by surgical excision, such as inoperable liver cancer, brain tumors, head and neck tumors, kidney tumors, and pancreatic cancer. Levels of activity may be accelerated to treat radiation-resistant solid tumors that may not respond well to conventional external-beam therapy.
The injectable radiogel may also be administered transdermally or intraoperatively when treating solid tumors that cannot be removed safely by surgical excision, such as inoperable liver cancer, brain tumors, head and neck tumors, kidney tumors, and pancreatic cancer. Levels of activity may be accelerated to treat radiation-resistant solid tumors that may not respond well to conventional external-beam therapy.
Yttrium-90 is a well-established medical isotope with many applications in cancer treatment. The combination of insoluble Yttrium-90 microspheres and the radiogel carrier offers physicians an opportunity to deliver a safe, effective treatment option at a low cost.
The late Dr. Robert Schenter, AMIC's Former Chief Scientific Officer, stated, "AMIC continues to develop the Yttrium-90 RadioGel™ line with Pacific Northwest National Laboratory, operated by Battelle. We believe that this product optimizes treatment of radiation-resistant tumors in vivo. We expect the RadioGel™ to become a therapeutic agent that provides physicians with the ability to effectively treat tumors that cannot be removed surgically or that cannot be treated by any other means."
According to AMIC the primary advantages of licensing these Yttrium-90 radiogels are multifold:
This treatment provides the ability to deliver a highly localized radiation therapy without irradiating nearby normal tissues - thereby achieving desired high therapeutic indices.
We are able to provide dose homogeneity within a solid tumor.
Because Yttrium-90 is a beta emitter, there is improved radiation safety for hospital personnel who prepare and handle the product.
Medical Isotopes:
AMIC is developing innovative approaches to the use, production and distribution of medical isotopes for advanced diagnostic and non-surgical therapeutic applications. A medical isotope is a radioactive substance used in very small quantities for safe, cost-effective medical imaging and treatment of disease.
The cornerstone equipment selected for the AMIC Production Facility is a proton linear accelerator. This proton linear accelerator is designed to replace large and cyclotron systems with significant infrastructure and utility requirements, such as electrical and air-handling, for the production of positron emitting isotopes. Large amounts of fluorine-18, carbon-11, nitrogen-13, and oxygen-15 can be produced for synthesis into compounds used in oncology, cardiology, neurology, and molecular imaging. The radio-labeled glucose analog, FDG, can be synthesized and distributed for use in Positron Emission Tomography. AMIC believes that no other accelerator in North America has sufficient flexibility to produce the full spectrum of PET imaging radioisotopes, as well as other high-demand isotopes, both short and long lived, for diagnostic and therapeutic applications.
From 2008 through 2013, AMIC manufactured and sold F-18 FDG from its Production Facility in its local region around Kennewick, WA. F-18 is an important isotope in the radiopharmaceutical industry, and is primarily synthesized into fluorodeoxyglucose (FDG) for use in positron emission tomography (PET) scans. FDG is the primary PET imaging isotope. It is used for medical and diagnostic purposes, such as cancer detection, heart imaging, and brain imaging. AMIC’s linear accelerator is capable of producing a variety of isotopes and future manufacturing and sales could expand beyond F-18 FDG. AMIC’s accelerator is currently off-line for maintenance and is expected to resume operations in late 2014.
The FDA has 120 days in which to make a decision, though the period will be extended for any time AMIC requires to respond to FDA requests for additional information.
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion.
AMIC's rights for the newly issued patent arise from its license from Battelle, under which AMIC exclusively licensed technologies developed at Pacific Northwest National Laboratory and the University of Utah for its proposed brachytherapy products. The patent awarded, US 8,821,364 B2, relates to AMIC's brachytherapy seed product and is entitled: Brachytherapy Seed with Fast Dissolving Matrix for Optimal Delivery of Radionuclides to Cancer Tissue. AMIC will support Battelle in further patent protection for additional markets consistent with AMIC's overall global commercialization strategy.
Battelle, has acquired approximately 11% of AMIC’s outstanding Common Stock. Battelle is a leading international science and technology enterprise that explores emerging areas of science and develops and commercializes technology.
""The Daily Chart With Full Analysis""
Players As We Get Ready For Next Week Keep One Thing In Mind And That Is ADMD Is In ""FLOAT LOCK DOWN MODE"".....Anybody That's Been Here For At Least 2 Weeks Can Tell You That The Accumulation Here Has Been INSANE""....,Hell One Day Last Week There Where Two 20Milly Bids That Was Filled, And I'm Not Even Sure How Many Shares The Officers Of The Company Owns Suffice To Say It's In The Millions!!
I'm Telling You Some Heavy Lifters Are In Here & Some Institutional Entities As Well,So They Want Your Shares BAD"""
...You Guys Seen How They Shook Out Weak Feeble Hands @ The Beginning Of The Trading Session On Friday By Painting a .0038 Gappa Buy & Then Dropping It Down To .0028 & How The Daytraders, And Flippers Tried To Bring It Down The Last 30min Of Trading On Friday Just To Try, And Get Back In On Monday To Do The Whole Damn Thing Over Again.....
Ahhhh But Little Did They Know The Longs ..,Strong Longs Drove The SP Back Up^ Only To Make Them Pay Mo $$$$ This Go' Round!!!!>>>LMFAO!!
So Players Take Your Time And Digest All This & The Chart Below!!
"" Let Us Not Forget This Players....>>>>>>>>>>>>>
AMIC is developing innovative approaches to the use, production and distribution of medical isotopes for advanced diagnostic and non-surgical therapeutic applications. A medical isotope is a radioactive substance used in very small quantities for safe, cost-effective medical imaging and treatment of disease.
The cornerstone equipment selected for the AMIC Production Facility is a proton linear accelerator. This proton linear accelerator is designed to replace large and cyclotron systems with significant infrastructure and utility requirements, such as electrical and air-handling, for the production of positron emitting isotopes.
Large amounts of fluorine-18, carbon-11, nitrogen-13, and oxygen-15 can be produced for synthesis into compounds used in oncology, cardiology, neurology, and molecular imaging. The radio-labeled glucose analog, FDG, can be synthesized and distributed for use in Positron Emission Tomography. AMIC believes that no other accelerator in North America has sufficient flexibility to produce the full spectrum of PET imaging radioisotopes, as well as other high-demand isotopes, both short and long lived, for diagnostic and therapeutic applications.
""There's Another Product That AMIC Manufactures's That Has Already Been FDA Approved I Think We Forgot About Players & That's The F-18 FDG (PET) Imaging Isotope That Was Taking Off Line Last Year For Maintenance, However Was Expected To Resume At The End Of 2014...We Should Be Hearing Some Sort Of Update On This Product Being Brought Back On Line Here Also!!!!""
From 2008 through 2013, AMIC manufactured and sold F-18 FDG from its Production Facility in its local region around Kennewick, WA. F-18 is an important isotope in the radiopharmaceutical industry, and is primarily synthesized into fluorodeoxyglucose (FDG) for use in positron emission tomography (PET) scans. FDG is the primary PET imaging isotope. It is used for medical and diagnostic purposes, such as cancer detection, heart imaging, and brain imaging. AMIC’s linear accelerator is capable of producing a variety of isotopes and future manufacturing and sales could expand beyond F-18 FDG. AMIC’s accelerator is currently off-line for maintenance and is expected to resume operations in late 2014.
The Pieces To The Puzzle Have All Been Assembled Here On VOIS, Now It's Going To Be Rolled Out To The Public According To The Last PR....The Next Few Weeks Here On VOIS Will Be The Tell..,Tell Sign On Where This Security Is Headed....
I Believe Once The International Community Gets Wind Of This Technology They Will Take The Lead On Buying Up^ What Is Left Of These Dreaded Notes, Or Note That Is Left Here On VOIS...Once This Is Done You Will See a Spike In The Accum/Dist Level Like Never Before Setting The Stage For a Massive Run North^....
The Mailers Going Out To Over 55K Investors Weekly Will Undoubtedly Help With This Accumulation Process, And May Leave Some Scrambling To Buy Shares Here On VOIS....Now Is The Time To Load & Hold On These Ridiculous SP's Of VOIS, Because Once The Process Gets Rolling There's No Stopping It!!!!!
I've Been Watching VOIS Daily Here In The Backround Observing The Action On L2 & I Believe We're Getting Very Close To That Ascension Journey That Will Carry VOIS To Pennyland Where a New Breed Of Investors Will Take Over & Drive VOIS Even Higher.....,How High You Ask?..,Well Your Guess Is As Good As Any!!!!!!
So Players The DD Has Been Exhausted & There's Not Much More To Say Other Than Hang Tight Be Strong & Hold Long, Because @ The End The Longs Will Prevail Here On VOIS!!!!
""Pimping Hard & Keeping The Game Real""
Smart..,Very Smart ADMD Will Make That Journey With Or Wihtout US!
Thanks Bro!...ADMD Is One Of Those Securities That Comes Along In a Time That Allows Players Like You & I To Be Part Of Something That Could Very Well Change Folks Lives.......Once FDA Approves The Y-90 RadioGel™ Device Not Only Will The Share Holders Prosper Ordinary People Like You & I Will Have a Chance At Life, And This My Friend Is Special Indeed!
Funny Thing Is It's Still March & ADMD Is Just Getting Organized For Something Very Special My Man..,And The Bears Made a Desperate Attempt Yesterday To Make a Run For Red..,But To No Avail, Because The Bulls Stepped Back In & Stole The Day Smooth As a Baby's As$~~~~~~~~~
I Suspect Next Week Will Be The Real Test To Rather The Bulls Can Stay In Control, I Personally Think They Have Enough Strength To Carry This Momentum For At Least Another Day Or Two, However You Know That a Catalyst Could Prove Me Wrong Easily.........We'll See~
"You Bet Your Sweet A%$ PP It Was, & Next Week Should Be Even Sweeter Here On ADMD!!!!
Indeed It Was My Friend.....ADMD Showed Up^ & Showed OUT!!
Exactly.....What More Can You Ask After 50% Gainer Yesterday & It's Friday To Boot~.....Say It With Me ADMD!
OMG!..>>>>>>>Wuzup Baby Girl!.....ADMD Better Get Sum!
""Amazing EOD Rally Over .0036 Which Was The Level To Hold Today.....I Mentioned It Earlier This Morning & It Was a Damn Battle All Damn Day Here On ADMD To Hold It, But We Did Prevail Players!....http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112155803
Monday Will Be Very Interesting Know That The Flippers Have Cashed Out For Mere Pennies On The Dollar....That 23K Bid Sitter Got Filled @ .0034 I Know Damn Well He's Happy!!!!..,Yet Another Fat Cat Here On ADMD With a Long List Of Others Including Yours Truly..<<<<<LMAO!!
Amazing ADMD Has Incredible Strength.., Even In The Closing Minutes Of Today She Held In The Midst Of Chaos Unrelenting Selling Right Into The Hands Of The Longs!!!!.....I Love It!!!!!,Bouncing Back STRONG Almost Closing @ The HOD Of .0038!
Players Charts Coming This Weekend Enjoy!
Unrelenting ""MASSIVE"" Accumulation Here Players On ADMD UNREAL<<
50K Was Just Picked Off Of The Bid & ADMD Is Still Standing Strong!!!!!
~~~~~~~~~~~~~~~~~~The Fuse Has Been Lit Here On ADMD"">>>>>>>>
""Ha Ha Ha LMFAO""....I Was Right Suspicion Confirmed That Was That 7Milly Bidder Hiding Behind That 10K Block With MM NITE @ .0034 Here On ADMD!!!!!
""Boy I'm Telling You ADMD 60min Chart Is Tighter Than a Little Sisters Under Plaummer Here On ADMD Players...<<<<<LMAO....The .0038 Break Is So Freakin Close!!!!!
Ok Guys I've Been Watching MM NITE On The Bid Here @ .0034 With That 10K Block Here On ADMD For Over 1hr Now & He Has Sucked Up^ Over 2Milly In Shares With That 10K Block Up^ There....
Two Things Here #1 Either That Whale With That 7Milly Bid Moved Up From .0033 To .0034 Hiding Behind That 10K Block Or #2 MM NITE Is Just Buying Up^ Everything That Is Sold @ Market Price..,Either Way It's a Win..,Win For Us In Terms Of Bid Support!!!!!
60min Chart Is Tightening PLayers That Massive Run Up^ Is Moments Away Here On ADMD....<<<<<<<Hold On Tight!!!!!
""There's a ""BULLSEYE"" On .0038 Here On ADMD!!!!